Objective: The aim of this study is to investigate the effect of Edaravone on viability of hepatocytes in experimental controlled non-heart beating donor models of rats and additionaly to determine the usefullness of these grafts. Material and Methods: Forty Wistar-Albino male rats, 225290 grams in weight were randomly assigned to five different groups (sham, two control and two study groups). Cardiac arrest was performed by intracardiac KCl injection (0.2 mL). Livers were subjected to 30 minutes of warm ischemia and were washed out with 50 mL Euro Collins solution via a portal vein catheter after total hepatectomy. Liver grafts in the control groups and the study groups were perfused with Histidin-Tryptophan- Ketoglutarat solution including SF and edaravone (1 mg/kg), respectively. The perfusion was lasted for 30 or 60 min using a circulatory system. AST, ALT, IL-10, IL-6, TNF-alpha levels were measured in the perfusion fluids. The grafts were saved under suitable conditions for histopathological assessment. Results: It was found that the Edaravone Groups have lower levels of AST, ALT, IL-6, and TNF-alpha and have higher levels of IL-10, PCNA labeling index, and Bcl-2 staining index when compared to Control Groups. Conclusion: Edaravone increases the viability of hepatocytes biochemically, morphologically in experimental controlled non-heart beating donor models of rats.
展开▼
